ST Pharm에스티팜
237690 · KOSDAQ · ₩237690 · 에스티팜
₩80,400▼ ₩8,100 (9.15%)End-of-day · Oct 27, 2026 · End-of-day prices.
Margins
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Gross margin | 40.1% | 41.1% | 35.1% | 39.3% | 35.7% | 34.9% |
| Operating margin | 18.3% | 16.6% | 10.1% | 11.8% | 7.2% | 3.4% |
| Net margin | 19.9% | 16.6% | 12.7% | 6.9% | 7.2% | 2.0% |
Growth (year on year)
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue growth | +16.5% | +21.2% | −3.9% | +14.3% | +50.5% | — |
| Operating income growth | +28.9% | +98.4% | −17.4% | +87.7% | +220.1% | — |
| Net income growth | +39.7% | +58.4% | +77.3% | +8.8% | +443.5% | — |
Returns
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Return on equity | 12.6% | 10.0% | 7.8% | 5.4% | 5.4% | 1.0% |
| Return on assets | 9.4% | 7.3% | 4.6% | 2.8% | 3.3% | 0.7% |
Leverage and liquidity
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Liabilities to equity | 34.8% | 32.0% | 43.5% | 74.6% | 67.3% | 52.9% |
| Net debt to equity | −17.6% | −2.4% | 0.8% | 25.5% | −1.5% | 20.6% |
| Current ratio | 227.9% | 226.2% | 247.7% | 416.0% | 151.4% | 323.9% |
Calculated from filed financial statements. TTM = trailing 12 months.
Also known as: ST Pharm / 에스티팜 / 237690 / KRX:237690
Source: KRX statistical information